Stocks › PCVX

Vaxcyte, Inc.

PCVX·Nasdaq·United States United States·USD
$55.39
-2.97 (-5.09%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
PCVX
Vaxcyte, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
PCVXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of PCVX by members of U.S. Congress · 9 on record · 3 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA PCVXVaxcyte, Inc. · Stock Purchase
$1,001 - $15,000
Sep 4, 2026 Jul 16, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA PCVXVaxcyte, Inc. · Stock Purchase
$1,001 - $15,000
Jun 8, 2026 May 13, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA PCVXVaxcyte, Inc. · Stock Purchase
$1,001 - $15,000
Jun 8, 2026 May 12, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA PCVXVaxcyte, Inc. · Stock Purchase
$1,001 - $15,000
May 6, 2025 Apr 14, 2025 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA PCVXVaxcyte, Inc. · Stock Purchase
$1,001 - $15,000
May 6, 2025 Apr 15, 2025 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA PCVXVaxcyte, Inc. · Stock Purchase
$1,001 - $15,000
May 6, 2025 Apr 28, 2025 Filing ↗
Jefferson ShreveJefferson ShreveHouse · R · IN PCVXVaxcyte, Inc. · Stock Sale
$15,001 - $50,000
Apr 11, 2025 Mar 5, 2025 Filing ↗
Christopher L. JacobsChristopher L. JacobsHouse · R · NY PCVXVaxcyte, Inc. · Stock Sale
$1,001 - $15,000
Jan 20, 2023 Dec 12, 2022 Filing ↗
Christopher L. JacobsChristopher L. JacobsHouse · R · NY PCVXVaxcyte, Inc. · Stock Purchase
$1,001 - $15,000
Dec 12, 2022 Nov 8, 2022 Filing ↗

Whale Activity

Position changes in PCVX reported for 2026-09-30 by 391 institutional filers
Increased: 128New: 59Held: 47Decreased: 102Closed: 35No prior filing: 20
  • Increased128
  • New59
  • Held47
  • Decreased102
  • Closed35
  • No prior filing20
FilerSharesValueChange
FMR LLC22.5M$1.28Bincreased
Janus Henderson Group Ltd.17.9M$1.02B—
T. Rowe Price Investment Management, Inc.14.3M$813.7Mincreased
BlackRock, Inc.12.2M$693.0Mincreased
RA CAPITAL MANAGEMENT, L.P.11.5M$652.9Mheld
WELLINGTON MANAGEMENT GROUP LLP7.7M$440.1Mincreased
VANGUARD CAPITAL MANAGEMENT LLC6.6M$373.9Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC6.6M$373.8Mdecreased
STATE STREET CORP5.2M$297.7Mdecreased
PRICE T ROWE ASSOCIATES INC /MD/3.5M$200.9Mincreased
Deep Track Capital, LP3.5M$199.9Mdecreased
GEODE CAPITAL MANAGEMENT, LLC3.5M$198.9Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by PCVX insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: -61.3K2025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: -21.4K2025 Q42026 Q1: -11.8K2026 Q12026 Q2: -67.4K2026 Q22026 Q3: -65.9K2026 Q32026 Q4: -61.5K2026 Q4

Recent Insider Transactions

938 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Dhaliwal Harpreet S.Chief Technical Ops Officer Sale −9,345 $68.16 $637K Nov 11, 2026 Form 4 ↗
Dhaliwal Harpreet S.Chief Technical Ops Officer Sale −7,135 $67.33 $480K Nov 11, 2026 Form 4 ↗
Dhaliwal Harpreet S.Chief Technical Ops Officer Sale −520 $68.82 $36K Nov 11, 2026 Form 4 ↗
Cowan ElviaSVP, Finance & CAO Sale −586 $61.55 $36K Nov 2, 2026 Form 4 ↗
Cowan ElviaSVP, Finance & CAO Sale −2,414 $60.77 $147K Nov 2, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Sale −343 $61.57 $21K Nov 2, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Sale −1,907 $60.78 $116K Nov 2, 2026 Form 4 ↗
Cowan ElviaSVP, Finance & CAO Sale −19.0K $86.74 $1.6M Oct 5, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Sale −18.0K $86.74 $1.6M Oct 5, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Sale −95 $57.09 $5K Oct 1, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Sale −2,155 $56.65 $122K Oct 1, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Sale −1,334 $59.52 $79K Sep 9, 2026 Form 4 ↗
Cowan ElviaSVP, Finance & CAO Tax withholding −1,327 $60.36 $80K Sep 8, 2026 Form 4 ↗
Dhaliwal Harpreet S.Chief Technical Ops Officer Tax withholding −7,651 $60.36 $462K Sep 8, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Tax withholding −5,459 $60.36 $330K Sep 8, 2026 Form 4 ↗
PICKERING GRANTCHIEF EXECUTIVE OFFICER · Director Tax withholding −17.1K $60.36 $1.0M Sep 8, 2026 Form 4 ↗
GUGGENHIME ANDREWPRESIDENT AND CFO Tax withholding −7,155 $60.36 $432K Sep 8, 2026 Form 4 ↗
Jodar LuisChief Medical Officer Grant / award +52.6K $0.00 $0 Sep 4, 2026 Form 4 ↗
Wassil JimEVP, Chief Scientific Ofc, COO Sale −1,381 $61.16 $84K Sep 4, 2026 Form 4 ↗
Cowan ElviaSVP, Finance & CAO Tax withholding −326 $61.58 $20K Sep 2, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding PCVX · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
4.6M$266.7M0.01%Jun 30, 2026
T. Rowe Price Capital Appreciation Fund
T. ROWE PRICE CAPITAL APPRECIATION FUND, INC.
4.0M$232.9M0.33%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
3.4M$197.2M0.24%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
3.3M$192.6M0.10%Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund
Fidelity Rutland Square Trust II
3.1M$191.1M0.07%Aug 31, 2026
Janus Henderson Forty Fund
Janus Investment Fund
2.7M$155.6M0.65%Jun 30, 2026
Janus Henderson Enterprise Fund
Janus Investment Fund
2.3M$131.9M0.59%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
2.2M$127.4M1.19%Jun 30, 2026
VANGUARD HEALTH CARE FUND
VANGUARD SPECIALIZED FUNDS
2.3M$126.6M0.33%Jul 31, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.9M$111.1M0.24%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list PCVX's shares (CUSIP 92243G108), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Wellington Investment Advisors Holdings LLPSCHEDULE 13G · passive (13G) · 7.7M shares5.2%
    Nov 16, 2026 · ↗
  • Wellington Group Holdings LLPSCHEDULE 13G · passive (13G) · 7.7M shares5.2%
    Nov 16, 2026 · ↗
  • Wellington Management Group LLPSCHEDULE 13G · passive (13G) · 7.7M shares5.2%
    Nov 16, 2026 · ↗
  • T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 18.1M shares11.6%
    Nov 6, 2026 · ↗
  • T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 14.3M shares9.6%
    Nov 6, 2026 · ↗
  • JANUS HENDERSON GROUP Ltd.SCHEDULE 13G/A · passive (13G) · 18.0M shares12.1%
    Aug 11, 2026 · ↗
  • JANUS HENDERSON GROUP Ltd.SCHEDULE 13G/A · passive (13G) · 65.7K shares0.1%
    Aug 7, 2026 · ↗
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 20.8M shares14.4%
    Aug 6, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 20.8M shares14.4%
    Aug 6, 2026 · ↗
  • RA Capital Healthcare Fund, L.P.SCHEDULE 13G/A · passive (13G) · 12.7M shares8.7%
    May 15, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming vaxcyte as client
$0$125K$250K$375K$500K2024 Q4: $30K20242025 Q1: $90K2025 Q2: $90K2025 Q3: $90K2025 Q4: $165K20252026 Q1: $155K2026 Q2: $155K2026 Q3: $155K2026
  • BGR GOVERNMENT AFFAIRSVAXCYTE, INC. · 2026 Q3 · HCR$80K
    Filing ↗
  • DCI GROUP, L.L.C.VAXCYTE, INC. · 2026 Q3 · HCR$75K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSVAXCYTE, INC. · 2026 Q2 · HCR$80K
    Filing ↗
  • DCI GROUP, L.L.C.VAXCYTE, INC. · 2026 Q2 · HCR$75K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSVAXCYTE, INC. · 2026 Q1 · HCR$80K
    Filing ↗

Government Contracts

Federal awards to Vaxcyte, Inc. · USAspending

No federal contract awards found for Vaxcyte, Inc..

U.S. Patents

Recent USPTO applications naming Vaxcyte, Inc.

No USPTO patent applications found for Vaxcyte, Inc..

Annual Financials

From PCVX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$923.7M-$569.5M-$468.0M-$232.3M-$103.7M
Net income-$766.6M-$463.9M-$402.3M-$223.5M-$100.1M
Diluted EPS-$5.63-$3.80-$4.14-$3.44-$1.93
Operating cash flow-$655.6M-$452.6M-$296.8M-$170.6M-$121.4M
Cash and equivalents$174.0M$387.9M$397.5M$834.7M$69.0M
Total assets$3.00B$3.51B$1.41B$1.01B$324.3M
Total liabilities$317.2M$205.5M$167.4M$52.6M$40.3M
Shareholders' equity$2.69B$3.31B$1.24B$953.6M$284.0M

As Vaxcyte, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in PCVX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03, 8.01, 9.01Material agreement · Direct financial obligation · Other eventsOct 9, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsOct 5, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 3, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeJul 15, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeJun 23, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 16, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
    EDGAR ↗

About Vaxcyte, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN CARLOS, CA
IncorporatedDE
Former namesSutroVax, Inc.